Tempus AI Inc

Análisis de la acción Tempus AI Inc (TEM)

$64.660

+2.839 (+4.39%)Al cierre

Loading chart…
High
64.813
Open
63.000
VWAP
63.55
Vol
4.89M
Mkt Cap
Low
61.190
Amount
310.77M
EV/EBITDA, TTM
-41.65

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

AI analysis of Tempus AI Inc (TEM)

buy

Tempus AI Inc is a good buy right now, trading at $64.04 with a strong analyst price target of $80, indicating a potential upside of 24.3%. The recent FDA clearance for their AI software enhances their market position, while a gross margin of 64.45% shows solid profitability potential. However, the main risk is the high debt-to-equity ratio of 305.82%, which indicates financial leverage that could impact stability.

Métricas de valoración

The current forward P/E ratio for Tempus AI Inc (TEM) is 0.00, compared to its 5-year average forward P/E of -97.78.

Forward P/E

Overvalued
5Y Average P/E
-97.78
Current P/E
0.00
Sobrevalorada
-43.08
Infravalorada
-152.47

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
41.33
Current EV/EBITDA
-41.65
Sobrevalorada
1321.41
Infravalorada
-1238.75

Forward P/S

Fair
5Y Average P/S
7.47
Current P/S
5.70
Sobrevalorada
9.66
Infravalorada
5.29

Whales holding TEM

L

Lingotto Investment Management LLP

+ HoldingTEM

+16.64%

3M Return

A

ARK Investment Management LLC

+ HoldingTEM

+11.64%

3M Return

P

Patient Capital Management, LLC

+ HoldingTEM

+5.67%

3M Return

C

Capital Impact Advisors, LLC

+ HoldingTEM

-0.69%

3M Return

A

Alphabet Inc.

+ HoldingTEM

-28.39%

3M Return

Cronología de eventos

2026-09-02 (ET)

15:00:00

Dell Technologies Raises Annual Sales Forecast by $25 Billion

2026-08-24 (ET)

09:00:00

Tempus AI Receives FDA Clearance for ECG-PH Software

2026-08-20 (ET)

12:30:00

Tempus AI Stock Rises 10.2% to $67.51

10:30:00

Tempus AI Stock Rises 9.5% to $67.04

2026-08-19 (ET)

12:30:00

Tempus AI Stock Rises 20.1% to $59.30

Noticias

TEM FAQ — answered by Alphio AI

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. It operates in the Healthcare sector.

Tempus AI Inc is a good buy right now, trading at $64.04 with a strong analyst price target of $80, indicating a potential upside of 24.3%. The recent FDA clearance for their AI software enhances their market position, while a gross margin of 64.45% shows solid profitability potential. However, the main risk is the high debt-to-equity ratio of 305.82%, which indicates financial leverage that could impact stability.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis